北交所策略专题报告 2026 年 02 月 06 日 掘金北交所后备军：三维视觉龙头先临三维及光器件鑫巨宏受理中 ——北交所新质生产力后备军筛选三十 北交所研究团队 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 北交所上市"后备军"214 家，分布在高端装备、TMT 等新质生产力行业中 截至 2026 年 2 月 1 日，北交所已有 214 家公司获受理，待上会企业 163 家，覆 盖高端装备（64 家）、TMT（27 家）、化工新材料（36 家）、消费（19 家）、生 物医药（12 家）等多元细分领域。受理和辅导中公司中，包含了一些新质生产 力公司，我们从中首选专精特新、单项冠军企业、"独角兽"企业。同时，我们 也着重关注氢能源、商业航天、低空经济等行业。 后备军筛选系列已 30 期，筛选出一批已经上市的新质生产力公司 在 2025 年北交所上市的 26 家公司中，本系列报告我们优选出星图测控、开发科 技、天工股份、广信科技、酉立智能、志高机械、宏远股份、能之光、三协电 机、世昌股份、锦华新材、江天科技等。其余优选公司中已过会公司包括：英氏 控股、雅图高新、 ...

Investment Rating - The report gives a "Buy" rating for Dongxing Medical [5] Core Viewpoints - Dongxing Medical is positioned as a micro-invasive surgical platform company with diversified layouts that promote growth. The company focuses on the anastomosis device industry chain and is gradually expanding into other micro-invasive surgical products, aiming to establish itself as a platform enterprise in medical devices [3][12] - The company plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., which has obtained 58 medical device registration certificates, enhancing its medical device platform and facilitating synergistic development [3][12] - The company has a concentrated shareholding structure and a professional management team, with expected revenue growth driven by product upgrades and cost control [3][12] Summary by Sections 1. Company Overview - Dongxing Medical has diversified its business since its establishment in 2001, transitioning from an agency model to a medical device manufacturer. The company has completed several acquisitions to integrate its supply chain, including the acquisition of Weike Medical and Zihang Precision, which closed the anastomosis device industry chain [12][19] - The company has a strong cash position, with cash and cash equivalents reaching 1.2 billion yuan, supporting future acquisitions [30][32] 2. Anastomosis Device Market - The anastomosis device market in China is expected to reach 9.82 billion yuan by 2024, with a compound annual growth rate (CAGR) of 8.1% from 2019 to 2024. The electric laparoscopic anastomosis device market is projected to grow significantly, with a CAGR of 44.4% during the same period [49][52] - The report indicates that the impact of centralized procurement on pricing has reached a turning point, with price adjustments stabilizing and the industry entering a phase of steady growth as penetration rates increase [54][55] 3. New Surgical Products - The company is expanding its product line to include ultrasonic knives, with a market size in the tens of billions. The domestic market for ultrasonic knives is rapidly increasing due to the rise in domestic production rates [5][12] - The company is also collaborating with Shanghai Jiao Tong University to develop synthetic biological materials, which are expected to be applied in serious medical fields such as hemostasis and scar repair, adding another growth point [5][12] 4. Financial Forecast and Valuation - The company forecasts revenues of 379 million yuan, 445 million yuan, and 512 million yuan for 2025, 2026, and 2027, respectively. The net profit attributable to shareholders is expected to be -37 million yuan, 94 million yuan, and 121 million yuan for the same years [5][8] - The report estimates a price-to-earnings (PE) ratio of 29x for 2026 based on the closing price on January 16, 2026 [5][8]

IPO Review and Registration Progress - Three companies passed the IPO review last week, including Zuxing New Materials, Mirui Technology, and Jintai Co., with Zuxing New Materials focusing on aluminum pigments and fine spherical aluminum powder, reporting revenue of 578 million yuan and net profit of 60 million yuan for the first three quarters of 2025, reflecting year-on-year growth of 10.98% and 35.47% respectively [3][4] - Mirui Technology, engaged in smart network cameras and IoT video products, reported revenue of 549 million yuan, a decline of 0.95%, and net profit of 51 million yuan, down 12.93% for the same period [4] - Jintai Co., specializing in sponge titanium products, achieved revenue of 1.272 billion yuan, up 12.43%, and net profit of 155 million yuan, an increase of 52.68% [4] New IPO Applications and Upcoming Reviews - Five new IPO applications were accepted last week, including Ma Mining Co., which focuses on iron ore resource development, reporting a revenue of 2.057 billion yuan and net profit of 659 million yuan from 2022 to 2024 [8][9] - Zhongke Kehua, a semiconductor packaging materials company, reported revenue of 331 million yuan and net profit of 34 million yuan for 2024, with plans to raise 598 million yuan through its IPO [9] - Yulong Technology, a precision control board manufacturer, reported revenue of 1.095 billion yuan and net profit of 121 million yuan for the first half of 2025, with a significant portion of its revenue coming from BOE Technology Group [10][11] New Stock Subscription and Listing Dynamics - Three new stocks were listed last week, including Jingchuang Electric, which saw a price increase of 330.74% on its first day, and China Uranium Industry, which rose by 280.04% [13] - This week, five new stocks are scheduled for subscription, including Yuxun Co., which focuses on optical communication chips and expects a net profit of 92 million to 98 million yuan for 2025, reflecting a year-on-year growth of 18.15% to 25.86% [14][15]

Core Viewpoint - Hainan Baimaike Medical Technology Co., Ltd. has received acceptance for its IPO on the Beijing Stock Exchange, indicating a significant step in its growth and expansion strategy [2] Financial Performance - The company reported revenues of 90.68 million yuan in 2022, projected to increase to 174 million yuan in 2023 and 185 million yuan in 2024, with a slight decline to 95.81 million yuan in the first half of 2025 [3] - Net profit for the same periods is expected to be 29.50 million yuan in 2022, rising to 70.18 million yuan in 2023, then slightly decreasing to 69.19 million yuan in 2024, and 34.99 million yuan in the first half of 2025 [3] Balance Sheet Highlights - Total assets increased from 168.80 million yuan in 2022 to 379.19 million yuan by June 30, 2025, reflecting strong growth [4] - Shareholder equity rose significantly from 85.05 million yuan in 2022 to 318.48 million yuan in mid-2025, indicating improved financial stability [4] - The company's debt-to-asset ratio decreased from 47.46% in 2022 to 10.97% in mid-2025, showcasing a stronger balance sheet [4] Profitability Metrics - The gross profit margin remained high, with 75.97% in the first half of 2025, compared to 76.52% in 2022 [4] - The return on equity (ROE) was 11.25% in the first half of 2025, down from 60.84% in 2023, indicating fluctuations in profitability [5] - Basic earnings per share (EPS) were reported at 0.86 yuan for the first half of 2025, compared to 1.84 yuan in 2023 [5] R&D Investment - Research and development expenses accounted for 15.43% of revenue in the first half of 2025, up from 11.55% in 2022, highlighting the company's commitment to innovation [5] Management and Control - The company's actual controller, Yang Dingjian, holds 7.33% of the total shares directly and controls 60.99% of the voting rights through various entities [5][6]

Core Viewpoint - Hainan Baimaike Medical Technology Co., Ltd. has received acceptance for its IPO on the Beijing Stock Exchange, indicating a significant step towards public listing and capital raising for the company [1] Company Overview - Baimaike is a high-tech enterprise specializing in the research, production, and sales of surgical medical devices, particularly surgical sutures, and peptide pharmaceutical equipment [1] - The main products of the company include surgical sutures, interventional embolization materials, hemostatic materials, as well as peptide synthesis instruments and peptide cleavage instruments [1]

Core Insights - The New Third Board has welcomed a number of hard technology companies, with 15 new listings in the past week, including six companies on October 22, showcasing strong innovation and market competitiveness in sectors like semiconductors and advanced manufacturing [1][2] - The New Third Board is increasingly demonstrating its role in nurturing hard technology enterprises, as exemplified by companies like Loco Electronics, which focuses on intelligent oil and gas field equipment [1][2] - Several newly listed companies are actively preparing for listings on the Beijing Stock Exchange, indicating a deepening linkage between the New Third Board and the Beijing Stock Exchange [1][6] Company Highlights - Zhongxin Crystal, a key player in semiconductor wafer manufacturing, has established a comprehensive production process and plans to reach a monthly capacity of 400,000 small-sized wafers and 600,000 12-inch polished wafers [2][3] - Zhongxin Crystal has entered the supply chain of major clients, including SMIC and GlobalWafers, with over 270 certified customers and 2,600 certified products [2] - Xinxing Lianhua, recognized as a national "little giant," specializes in high-frequency and high-speed electronic testing instruments, demonstrating significant technical advantages in the high-end radio instrument market [3] - Sentai Yingge is a rare domestic enterprise capable of providing precision accessories for CNC machine tools, with applications in automotive manufacturing and aerospace [3] - Haimingrun has established a leading position in diamond composite sheets for oil and gas drill bits, focusing on the mid-to-high-end market [4] - Weifang Jinghua is a major manufacturer of negative electrode material crushing equipment, becoming a key supplier for global leader BETTERI in the negative electrode materials sector [4] Progress on Beijing Stock Exchange Listings - Zhongxin Crystal has initiated its listing preparation for the Beijing Stock Exchange, having submitted its application on August 1 and received acceptance on October 10 [6] - Other newly listed companies are also advancing their plans for the Beijing Stock Exchange, with several updating their listing progress in October [6] - Zhu Bingren Copper, listed on October 15, announced the submission of its listing application the day after its listing, focusing on copper crafts and decorative products [6] - Baimaike's board approved a listing proposal for the Beijing Stock Exchange, with a high gross margin of 75.97% and multiple certifications [6] - Ruilong Technology, listed on October 17, plans to submit its application for the Beijing Stock Exchange within 12 months, having established itself in the high-frequency copper-clad laminate industry [7]

Summary of Key Points from Conference Call Records Industry Overview - **Industry Focus**: Minimally Invasive Surgery (MIS) and Pharmaceutical Industry - **Market Size**: The domestic minimally invasive surgery market is projected to grow from 236 billion to 407 billion by 2028, with a compound annual growth rate (CAGR) of 11.5% [22] - **Current Market Dynamics**: The pharmaceutical industry is currently ranked 23rd among 31 primary industries, with innovation drugs and related sectors showing relative strength [2] Core Insights and Arguments Innovation Drugs - **Market Performance**: The innovation drug sector is highlighted as the biggest bright spot in the pharmaceutical industry, with strong fundamentals and ongoing market activity despite recent corrections [3][5] - **Future Outlook**: After recent adjustments, a second wave of growth is anticipated, driven by the sector's ability to catch up and surpass global leaders [5] Medical Devices - **Sector Improvement**: The medical device sector is experiencing continuous month-on-month improvement, with significant year-on-year growth expected in Q3 [6] - **Key Areas of Focus**: High-end medical imaging equipment, AI medical devices, and surgical robots are recommended areas for investment, with companies like Mindray, United Imaging, and Aohua highlighted [10] Raw Materials - **Market Sentiment**: The raw materials sector is viewed positively, with prices stabilizing after a period of decline and production capacity utilization improving [15] - **Growth Drivers**: Key growth points include new products from expired patents, integrated formulation businesses, and cost-leading CDMO (Contract Development and Manufacturing Organization) models [15][16] Traditional Chinese Medicine (TCM) - **Performance Expectations**: The TCM sector is expected to improve in the second half of the year due to declining procurement costs and lower performance baselines from the previous year [11] - **Recommended Companies**: Companies such as China Resources Sanjiu, Mayinglong, Kangyuan, and Tianshili are recommended, with valuations around 15 times earnings [12] Retail Pharmacy - **Trends**: The pace of store closures in offline retail pharmacies is expected to increase, with a long-term trend towards greater concentration among leading players [13] - **Online Impact**: Online channels are anticipated to continue replacing offline sales, driven by healthcare reforms and major players' investments [14] Additional Important Insights - **Minimally Invasive Surgery Growth Factors**: The growth in minimally invasive surgeries is driven by an aging population and increasing penetration rates, with current penetration at 44% in China compared to 81% in the U.S. [19] - **Market Competition**: The minimally invasive surgery market is dominated by foreign companies, with Johnson & Johnson, Medtronic, and B. Braun holding over 50% market share. Domestic players like Kangji Medical and Mindray are emerging as significant competitors [23] - **Domestic Production Impact**: The domestic production process is expected to enhance market penetration and reduce costs, with significant increases in local production rates for various surgical instruments anticipated by 2024 [24]

Group 1: Weiwodun Petroleum Technology Co., Ltd. - Weiwodun is founded by an alumnus of Southwest Petroleum University and has initiated IPO counseling with ShenGang Securities, aiming for an IPO on the Beijing Stock Exchange [3] - Established in April 2006, Weiwodun is a national-level specialized and innovative "little giant" enterprise focusing on the R&D, production, and sales of oil and gas extraction reservoir modification agents and tools [4] - The company has experienced significant revenue fluctuations, with projected revenues of 146 million, 171 million, 166 million, and 225 million yuan from 2021 to 2024, and net profits declining for two consecutive years [4] Group 2: Aisida Aerospace Technology Co., Ltd. - Aisida Aerospace has completed IPO counseling with CITIC Securities, targeting an IPO on the Sci-Tech Innovation Board [6] - Founded in 2018, Aisida specializes in lightweight structures and functional products made from carbon fiber composite materials, primarily producing rocket fairings [6][7] - The company has supported multiple successful rocket launches, including significant missions for various commercial aerospace companies [7] Group 3: Xinnowei Pharmaceutical Technology Co., Ltd. - Xinnowei has submitted its IPO counseling materials, aiming for an A-share listing with Guotai Junan as the counseling institution [14] - Established in May 2017, Xinnowei focuses on innovative drug development in oncology, multi-drug resistant bacterial infections, and metabolic diseases, with 10 drug candidates in clinical research [14] - The company has raised over 2 billion yuan in funding since its inception, with significant investments from various venture capital firms [15] Group 4: Zhongke Innovation Technology Co., Ltd. - Zhongke Innovation has submitted its IPO counseling report to the Hubei Securities Regulatory Bureau, with Dongwu Securities as the counseling institution [16] - Founded in April 2003, the company specializes in non-destructive testing equipment and customized solutions, achieving revenue growth of 15% over two years [17] Group 5: Youbang Radiator (Changshu) Co., Ltd. - Youbang has completed IPO counseling with CITIC Securities, planning to list on the Beijing Stock Exchange [18] - Established in 1997, Youbang is a leading manufacturer of transformers and radiators, holding an 18.9% market share in China [19] - The company has shown consistent revenue growth, with projected revenues of 235 million, 277 million, and 315 million yuan from 2022 to 2024 [20] Group 6: Baimaike Medical Technology Co., Ltd. - Baimaike has submitted its IPO counseling materials to the Hainan Regulatory Bureau, with Changcheng Securities as the counseling institution [21] - The company specializes in surgical medical devices and peptide pharmaceutical equipment, with a focus on innovative product development [22] - Baimaike has achieved revenues of 90.67 million, 174 million, and 185 million yuan from 2022 to 2024, with a significant market presence in absorbable surgical sutures [23] Group 7: Ruiniu Co., Ltd. - Ruiniu has submitted its IPO counseling materials to the Jiangsu Regulatory Bureau, with Everbright Securities as the counseling institution [25] - Founded in 2006, Ruiniu is a leading manufacturer in the agricultural machinery belt industry, with significant clients including major agricultural machinery companies [26] - The company has reported revenues of 288 million, 308 million, 235 million, and 306 million yuan from 2021 to 2024, with a notable decline in performance in recent years [28]